SYD985 与多个主题相关，在 HER2 阳性转移性乳腺癌治疗中显示出积极结果，在联合免疫治疗和不同恶性肿瘤治疗方面具有潜力。此外，还有针对 Trop2、HER3、B7-H4 等靶点的 ADC 药物，如 Sacituzumab govitecan（SG）在 HER2 低表达乳腺癌治疗中也有潜力，但需明确 T-DXd 和 SG ...

HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...